Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Share News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Regent Pacific To Acquire Plethora Solutions For GBP114.3 Million

Tue, 15th Dec 2015 13:47

LONDON (Alliance News) - Regent Pacific Group Ltd on Tuesday said it has agreed to acquire the shares it doesn't already own in Plethora Solutions Holdings PLC, valuing the premature ejaculation treatment company at 11.65 pence per share.

The deal values Plethora at about GBP95.9 million, based on the number of shares in issue, and at GBP114.3 million when considering its fully diluted share capital. Shareholders in Plethora will receive 15.7076 new Regent Pacific shares for each Plethora share they own. Shares in Plethora jumped by 18% to 5.30p on Tuesday afternoon.

The deal comes about six weeks after the companies said they had agreed on the key terms of a possible deal.

James Mellon is the non-executive chairman of Plethora and non-executive co-chairman of Regent Pacific, and Jamie Gibson is an executive director and the chief executive of both companies. Plethora's main product is PSD502, a treatment for premature ejaculation.

On completion of the offer, Plethora shareholders other than Regent Pacific will own about 65.98% of the combined group.

"This offer is about optimising growth and realising the potential of an innovative product that can address a known medical condition affecting almost one in four men. With increased investment and commercial innovation, we see huge scope for the product initially in Europe where it has approval, and in the important US market and in the fast growing Asian market in due course," James Mellon said.

"We view the offer as taking account of PSD502TM's prospects, while also providing a compelling premium of more than 38% to the price at which Plethora's last issued shares in August 2014 and we believe it will create significantly more future value than Plethora could achieve independently," Mellon added.

Michael Wyllie, chief science officer at Plethora, said the deal presents an "achievable solution to its difficult financial position whilst providing shareholders an opportunity to maintain an ongoing economic interest in Plethora and its product".

By Samuel Agini; samagini@alliancenews.com; @samuelagini

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
19 Nov 2013 08:07

AIM IN BRIEF: Centamin Further Reduces Stake In Nyota Minerals

Read more
30 Sep 2013 13:34

Plethora Cuts Losses As It Focuses Entirely Premature Ejaculation Treatment

Read more
23 Sep 2013 12:12

UK WINNERS & LOSERS: Ariana Resources Stands Out From Weak Gold Miners

Read more
20 Sep 2013 13:06

MARKET COMMENT: UK Trades Flat Prior To US Open; Nyota, Plethora Lead AIM

Read more
20 Sep 2013 12:43

Plethora Solutions Premature Ejaculation Spray Gets Positive Opinion

Read more
20 Sep 2013 12:26

UPDATE 1-New Roche breast cancer drug wins backing in Europe and Japan

* Kadcyla approved in Japan, recommended for approval in EU * EU agency also backs Algeta/Bayer prostate cancer drug LONDON, Sept 20 (Reuters) - Roche's new breast cancer drug Kadcyla was approved in Japan on Friday and recommended for approval in Europe, building on February's U.S. g

Read more
12 Apr 2013 11:50

Plethora Solutions Chairman resigns

Plethora Solutions Holdings Chairman Bill Robinson is stepping down from his role at the pharmaceuticals company. Jim Mellon will take over as Chairman with immediate effect temporarily until a successor is found. Robinson, who has been Chairman since 2009, will remain a Non-Executive Director of

Read more
18 Mar 2013 14:25

Plethora Solutions secures much needed financing

Plethora Solutions has secured 2.1m pounds in funding after its subsidiary The Urology Co. fell into administration. The funds were raised through the placing of 106.2m new ordinary shares at a price of 2.0p per share, representing an 8.0% interest. It comes after the company announced it was in

Read more
14 Feb 2013 08:24

Plethora Solutions shares jump following new equity update

Shares in pharmaceuticals company Plethora Solutions jumped sharply on Thursday after the group reported that it was in 'advanced discussions' with an investor to provide new equity financing to the group. The group, whose share price had recently been declining, added that support was also being s

Read more
5 Feb 2013 11:07

Plethora Solutions shares plunge on urgent financing talks

Plethora Solutions is in urgent discussions with third parties to finance the company's working capital purposes. Shares in the pharmaceutical company plummeted 55.00% to 2.25p at 11:18 following Tuesday's announcement. The company said it remained focused on the development of SD502, a drug for

Read more
17 Oct 2012 15:15

Plethora's PSD502 drug has mass market potential

Plethora Solutions is definitely a small cap stock to watch and in an exclusive interview with Sharecast, Daniel Stewart analyst Vadim Alexandre has reiterated the bull case for the biotech tiddler. Plethora Solutions has a drug, PSD502, aimed at treating premature ejaculation, which has passed two

Read more
15 Mar 2012 12:06

Small caps round-up: HMV, Corero, ANGLE ...

HMV Group, the struggling entertainment media seller, has confirmed that it is still pondering what to do with its live music business. HMV added that a number of parties have indicated an interest in acquiring the business. There has been press speculation recently about who might be interested in

Read more
14 Mar 2011 17:36

Plethora's testosterone boost

AIM-quoted sexual health products developer and distributor Plethora Solutions has added the pan-European rights for testosterone replacement treatment Striant SR to the UK rights it already has. Plethora has secured the rights from Columbia Laboratories and it will sell the product through its di

Read more
7 Sep 2010 13:48

Small caps round-up: Charlemagne, Highams, Hydro...

Hedge fund manager Charlemagne's assets under management rise have picked up in the past two months to stand at $3.04bn at end August. The modest recovery follows a fall in the first half to $2.8bn, blamed on declining markets. Operating profits were $1.2m, down from $1.3m, with one-off performanc

Read more
19 Jul 2010 07:25

Plethora Solutions Launches New Product, hi-Argenol >PLE.LN

LONDON (Dow Jones)--Plethora Solutions Holdings PLC (PLE.LN), a U.K.-based specialty pharmaceutical company, said Monday it has launched a new product, hi-Argenol, for the maintenance and improvement of male sexual health. -Shares closed Friday at 11.75 pence valuing the company at GBP5.21 milli

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.